Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells

NCT01640405 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

350

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: modified FOLFOX6 + bevacizumab
DRUG: FOLFOXIRI + Bevacizumab

Sponsor

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Collaborators

[object Object]